Zhong_2019

Supportive Therapie · Version 2.1

Referenz

(Autor, Jahr, Journal)

Studientyp

Mono- vs. Multizentrisch, Verblindung, Randomisierung, Arme, Fallzahl n, Land, Zeitraum

 

Patienten-merkmale

Indikation, Alter, Geschlecht (m/w)

Intervention

Fallzahl n, Beschreibung der präventiven bzw. therapeutischen Maßnahme

Kontrolle

Fallzahl n, Beschreibung der präventiven Maßnahme bzw. therapeutischen Maßnahme

Zielgrößen

Primärer Endpunkt

Sekundäre(r) Endpunkt(e)

Primärer Endpunkt

Angaben für Intervention vs. Kontrolle

Sekundäre(r) Endpunkt(e)

Angaben für Intervention vs. Kontrolle

Finanzierung

Evidenzstufe

Bei Abwertung: Angabe von Gründen

Bewertung des Autors

Zhong

 

2019

 

World J Gastroenterol

retrospective study

 

single centre

 

n = 45

 

China

 

01/2013 – 10/2017

 

Chronic radiation proctitis (CRP)

 

radiotherapy for gynecological malignancies: 88.9% of pts (cervical (n = 39) and vaginal (n = 1) cancers)

 

prostate cancer: 5 pts

 

median age: 60 years (range: 43-88 years)

 

Argon plasma coagulation (APC)

 

long-term efficacy and safety of APC for hemorrhagic CRP

median duration between cessation of radiotherapy and onset of radiation proctitis: 8 mo (range: 0-78 mo)

 

median follow-up time from the most recent APC procedure: 24 mo (range: 12-67 mo)

 

median hemoglobin level at the time of first APC treatment: 10.1 g/dL (2.8-13.1 g/dL)

 

patients required blood transfusion: 15 (33.3%)

 

blood transfusion before APC: 15 (33.3%) pts

 

Successful treatment with APC: 31 (68.9%) pts

Mean number of APC sessions: 1.3 (1-3)

 

APC failure associated with… telangiectasias present on more than 50% of the surface area [odds ratio (OR) = 6.53, 95% confidence interval (CI): 1.09-39.19, P = 0.04]

 

ulcerated area greater than 1 cm2  (OR = 8.15, 95%CI: 1.63-40.88, P = 0.01).

 

severe complications involving rectal fistulation: 6 (13.3%)

National Natural

Science Foundation of China, No.

81573078; and the National Natural

Science Foundation of Guangdong

Province, No. 2016A030311021.

3

retrospective design and a relatively small
number of cases

 

"The long-term efficacy of APC for hemorrhagic CRP is uncertain in patients with telangiectasias present on > 50% of the surface area and ulceration > 1 cm2."